Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Liu, C.; Yang, M.; Zhang, D.; Chen, M.; Zhu, D. Clinical cancer immunotherapy: Current progress and prospects. Front. Immunol. 2022, 13, 961805. [Google Scholar] [CrossRef]
- Lee, Y.R. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma. J. Liver Cancer 2023, 23, 316–329. [Google Scholar] [CrossRef] [PubMed]
- Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [Google Scholar] [CrossRef] [PubMed]
- Korean Liver Cancer Association; National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer 2023, 23, 1–120. [Google Scholar] [CrossRef]
- Martins, F.; Sofiya, L.; Sykiotis, G.P.; Lamine, F.; Maillard, M.; Fraga, M.; Shabafrouz, K.; Ribi, C.; Cairoli, A.; Guex-Crosier, Y.; et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 2019, 16, 563–580. [Google Scholar] [CrossRef] [PubMed]
- Song, Y.G.; Yoo, J.J.; Kim, S.G.; Kim, Y.S. Complications of immunotherapy in advanced hepatocellular carcinoma. J. Liver Cancer 2024, 24, 9–16. [Google Scholar] [CrossRef] [PubMed]
- Song, Y.-G.; Yeom, K.-M.; Jung, E.A.; Kim, S.G.; Kim, Y.S.; Yoo, J.-J. Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis. Liver Cancer 2024, 1–11. [Google Scholar] [CrossRef]
- Pallin, D.J.; Baugh, C.W.; Postow, M.A.; Caterino, J.M.; Erickson, T.B.; Lyman, G.H. Immune-related Adverse Events in Cancer Patients. Acad. Emerg. Med. 2018, 25, 819–827. [Google Scholar] [CrossRef]
- Som, A.; Mandaliya, R.; Alsaadi, D.; Farshidpour, M.; Charabaty, A.; Malhotra, N.; Mattar, M.C. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J. Clin. Cases 2019, 7, 405–418. [Google Scholar] [CrossRef]
- Yu, K.; Mathew, A.; Abraham, F.; Amin, R.; Kono, M.; Overman, M.; Zhao, D.; Khan, A.; Khan, M.A.; Thomas, A.S.; et al. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann. Gastroenterol. 2022, 35, 514–521. [Google Scholar] [CrossRef]
- Yamauchi, R.; Araki, T.; Mitsuyama, K.; Tokito, T.; Ishii, H.; Yoshioka, S.; Kuwaki, K.; Mori, A.; Yoshimura, T.; Tsuruta, O.; et al. The characteristics of nivolumab-induced colitis: An evaluation of three cases and a literature review. BMC Gastroenterol. 2018, 18, 135. [Google Scholar] [CrossRef]
- Steiger, S.; Marcucci, V.; Desai, V.; Zheng, M.; Parker, G. Refractory Fulminant Colitis Requiring Surgical Intervention in a Patient With Ulcerative Colitis on Atezolizumab Therapy for Small Cell Lung Cancer: An Atypical Case. Cureus 2022, 14, e25437. [Google Scholar] [CrossRef] [PubMed]
- Pentapati, S.; Caucci, S.; Balmuri, S.; Devarkonda, V. Complete Remission of Advanced Hepatocellular Carcinoma in a Patient with Ulcerative Colitis Treated With Atezolizumab and Bevacizumab: A Case Report. Cureus 2023, 15, e39538. [Google Scholar] [CrossRef] [PubMed]
- Kubo, K.; Kato, M.; Mabe, K. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2017, 15, A35–A36. [Google Scholar] [CrossRef]
- Fuji, T.; Arai, J.; Otoyama, Y.; Nio, Y.; Sugiura, I.; Nakajima, Y.; Kajiwara, A.; Ichikawa, Y.; Uozumi, S.; Shimozuma, Y.; et al. A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review. Onco Targets Ther. 2022, 15, 1281–1288. [Google Scholar] [CrossRef]
- Gallo, A.; Talerico, R.; Novello, L.; Giustiniani, M.C.; D’Argento, E.; Bria, E.; Montalto, M. Collagenous colitis and atezolizumab therapy: An atypical case. Clin. J. Gastroenterol. 2021, 14, 165–169. [Google Scholar] [CrossRef] [PubMed]
- Tang, L.; Wang, J.; Lin, N.; Zhou, Y.; He, W.; Liu, J.; Ma, X. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Front. Immunol. 2021, 12, 800879. [Google Scholar] [CrossRef]
- Hone Lopez, S.; Kats-Ugurlu, G.; Renken, R.J.; Buikema, H.J.; de Groot, M.R.; Visschedijk, M.C.; Dijkstra, G.; Jalving, M.; de Haan, J.J. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch. 2021, 479, 1119–1129. [Google Scholar] [CrossRef]
- Nielsen, D.L.; Juhl, C.B.; Chen, I.M.; Kellermann, L.; Nielsen, O.H. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treat. Rev. 2022, 109, 102440. [Google Scholar] [CrossRef]
- Zou, F.; Wang, X.; Glitza Oliva, I.C.; McQuade, J.L.; Wang, J.; Zhang, H.C.; Thompson, J.A.; Thomas, A.S.; Wang, Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J. Immunother. Cancer 2021, 9, e002058. [Google Scholar] [CrossRef]
- Nishida, T.; Iijima, H.; Adachi, S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J. Gastrointest. Pathophysiol. 2019, 10, 17–28. [Google Scholar] [CrossRef] [PubMed]
- Grover, S.; Wang, Y.; Dougan, M. Immune Checkpoint Inhibitor Colitis; UpToDate: Waltham, MA, USA, 2024. [Google Scholar]
- Bellaguarda, E.; Hanauer, S. Checkpoint Inhibitor-Induced Colitis. Am. J. Gastroenterol. 2020, 115, 202–210. [Google Scholar] [CrossRef]
- Sasson, S.C.; Slevin, S.M.; Cheung, V.T.F.; Nassiri, I.; Olsson-Brown, A.; Fryer, E.; Ferreira, R.C.; Trzupek, D.; Gupta, T.; Al-Hillawi, L.; et al. Interferon-Gamma-Producing CD8(+) Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis. Gastroenterology 2021, 161, 1229–1244.e1229. [Google Scholar] [CrossRef]
- Dougan, M.; Wang, Y.; Rubio-Tapia, A.; Lim, J.K. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2021, 160, 1384–1393. [Google Scholar] [CrossRef]
- Geukes Foppen, M.H.; Rozeman, E.A.; van Wilpe, S.; Postma, C.; Snaebjornsson, P.; van Thienen, J.V.; van Leerdam, M.E.; van den Heuvel, M.; Blank, C.U.; van Dieren, J.; et al. Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management. ESMO Open 2018, 3, e000278. [Google Scholar] [CrossRef]
- Johnson, D.H.; Zobniw, C.M.; Trinh, V.A.; Ma, J.; Bassett, R.L., Jr.; Abdel-Wahab, N.; Anderson, J.; Davis, J.E.; Joseph, J.; Uemura, M.; et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J. Immunother. Cancer 2018, 6, 103. [Google Scholar] [CrossRef] [PubMed]
- Abu-Sbeih, H.; Ali, F.S.; Alsaadi, D.; Jennings, J.; Luo, W.; Gong, Z.; Richards, D.M.; Charabaty, A.; Wang, Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: A multi-center study. J. Immunother. Cancer 2018, 6, 142. [Google Scholar] [CrossRef] [PubMed]
- Thomas Anusha, S.; Ma, W.; Wang, Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N. Engl. J. Med. 2021, 384, 581–583. [Google Scholar] [CrossRef]
- Céspedes Martínez, E.; Robles Alonso, V.; Herrera-De Guise, C.; Mayorga, L.; Casellas, F.; Roca-Herrera, M.; Borruel, N. Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: Clinical experience in a tertiary referral hospital. Rev. Esp. Enferm. Dig. 2023, 115, 567–573. [Google Scholar] [CrossRef]
- Fernández-Gordón Sánchez, F.M.; Gómez-Domínguez, E.; Paredes Ruiz, D.; Rodríguez Gil, Y.; Martín Algíbez, A.; Fernández Vázquez, I.; Martínez Montiel, P. Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev. Esp. Enferm. Dig. 2022, 114, 356–357. [Google Scholar] [CrossRef]
- Halsey, T.M.; Thomas, A.S.; Hayase, T.; Ma, W.; Abu-Sbeih, H.; Sun, B.; Parra, E.R.; Jiang, Z.D.; DuPont, H.L.; Sanchez, C.; et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci. Transl. Med. 2023, 15, eabq4006. [Google Scholar] [CrossRef] [PubMed]
- Burla, J.; Bluemel, S.; Biedermann, L.; Barysch, M.J.; Dummer, R.; Levesque, M.P.; Gubler, C.; Morell, B.; Rogler, G.; Scharl, M. Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflamm. Intest. Dis. 2020, 5, 109–116. [Google Scholar] [CrossRef] [PubMed]
- Abu-Sbeih, H.; Ali, F.S.; Naqash, A.R.; Owen, D.H.; Patel, S.; Otterson, G.A.; Kendra, K.; Ricciuti, B.; Chiari, R.; De Giglio, A.; et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J. Clin. Oncol. 2019, 37, 2738–2745. [Google Scholar] [CrossRef] [PubMed]
Year | Country | Sex/Age | Type of Cancer | Onset | Treatment | Prognosis | Discontinuation of Immunotherapy | Ref. |
---|---|---|---|---|---|---|---|---|
2022 | Japan | M/89 | HCC | After sixth administration of atezolizumab/bevacizumab: 1200 mg, 15 mg/kg | Systemic steroid (prednisolone) | Completely recovered | Resumed chemotherapy | Fuji et al. [15] |
2021 | Italy | F/57 | NSCLC (adenocarcinoma) | Two weeks after start of atezolizumab monotherapy, dose unknown | Systemic steroid (methylprednisolone and prednisolone) | Completely recovered | Held chemotherapy | Gallo et al. [16] |
2022 | USA | F/59 | SCLC | Four weeks after start of atezolizumab monotherapy, dose unknown | Total colectomy and end-ileostomy | Refractory to systemic steroid and biologics (infliximab, vedolizumab) | Undescribed | Steiger et al. [12] * previous uncontrolled UC |
2024 | South Korea | M/54 | HCC | After second administration of atezolizumab/bevacizumab: 1200 mg, 15 mg/kg | Systemic steroid (methylprednisolone and prednisolone) | Completely recovered | Resumed chemotherapy | The case reported in this study |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, H.; Shin, Y.E.; Yoo, H.-J.; Kim, J.-Y.; Yoo, J.-J.; Kim, S.G.; Kim, Y.S. Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review. Medicina 2024, 60, 1422. https://doi.org/10.3390/medicina60091422
Kim H, Shin YE, Yoo H-J, Kim J-Y, Yoo J-J, Kim SG, Kim YS. Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review. Medicina. 2024; 60(9):1422. https://doi.org/10.3390/medicina60091422
Chicago/Turabian StyleKim, Hyuk, Yoon E Shin, Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, and Young Seok Kim. 2024. "Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review" Medicina 60, no. 9: 1422. https://doi.org/10.3390/medicina60091422